About: MDX-1097

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.

Property Value
dbo:abstract
  • MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing. (en)
dbo:casNumber
  • 1793022-75-9
dbo:wikiPageID
  • 42634358 (xsd:integer)
dbo:wikiPageLength
  • 4263 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1032475924 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 1793022 (xsd:integer)
dbp:synonyms
  • IST-1097; KappaMab (en)
dbp:type
  • mab (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing. (en)
rdfs:label
  • MDX-1097 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License